Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > 2026 Vol. 4 > No. 2 > 100201
Next Article Previous Article
GUIDELINE SNAPSHOT   Open Access     Cite

Evidence-based guidelines for the diagnosis and management of primary central nervous system B-cell lymphoma

  • 1.

    Department of Basic Medicine, School of Medicine, Foshan University, Foshan 528000, China

  • 2.

    Department of Neurosurgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China

  • 3.

    Chongqing Health Center for Women and Children, Women and Children’s Hospital of Chongqing Medical University, Chongqing 401120, China

  • 4.

    Precision Oncology and Intelligent Theranostics Laboratory, Children’s Hospital of Chongqing Medical University, Chongqing 401122, China

  • 5.

    These authors contributed equally

More Information
  • Corresponding author: youhua307@163.com
  • Received Date:  September 29, 2025
    Accepted Date:  March 03, 2026
    Published Online:  March 04, 2026
The Innovation Medicine  4(2),  https://doi.org/10.59717/j.xinn-med.2026.100201  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Alaggio R., Amador C., Anagnostopoulos I., et al. (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36:1720−1748. DOI:10.1038/s41375-022-01620-2

    View in Article CrossRef Google Scholar

    [2] Lymphoid Disease Group, Chinese Society of Hematology, Chinese Medical Association; Lymphoma Expert Committee of Chinese Society of Clinical Oncology (CSCO). (2024). Chinese expert consensus on the diagnosis and treatment of primary central nervous system lymphoma (2024 version). Journal of Leukemia and Lymphoma 33:129−137. DOI:10.3760/cma.j.cn115356-20231019-00058

    View in Article CrossRef Google Scholar

    [3] Ferreri A.J.M., Calimeri T., Cwynarski K., et al. (2023). Primary central nervous system lymphoma. Nat. Rev. Dis. Primers 9:29. DOI:10.1038/s41572-023-00439-0

    View in Article CrossRef Google Scholar

    [4] Mishima K., Nishikawa R., Narita Y., et al. (2023). Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C. Neuro. Oncol. 25:687−698. DOI:10.1093/neuonc/noac246

    View in Article CrossRef Google Scholar

    [5] Bromberg J.E.C., Issa S., van der Holt B., et al. (2024). Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study. Neuro. Oncol. 26:724−734. DOI:10.1093/neuonc/noad224

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Yang H., Xun Y., Ke C., et al. (2026). Evidence-based guidelines for the diagnosis and management of primary central nervous system B-cell lymphoma. The Innovation Medicine 4:100201. https://doi.org/10.59717/j.xinn-med.2026.100201
    Yang H., Xun Y., Ke C., et al. (2026). Evidence-based guidelines for the diagnosis and management of primary central nervous system B-cell lymphoma. The Innovation Medicine 4:100201. https://doi.org/10.59717/j.xinn-med.2026.100201

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(2707) PDF downloads(3870)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.